Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sufentanil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 4/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.98 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.74 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sufentanil SCHEMBL27722103 | 0.99 | OPRM1 (1.00) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL26728 | 0.99 | OPRM1 (1.00) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28432948 | 0.98 | OPRM1 (0.98) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28438312 | 0.98 | OPRM1 (0.98) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL2727222 | 0.97 | OPRM1 (0.96) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28429542 | 0.95 | OPRM1 (0.91) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28429544 | 0.95 | OPRM1 (0.91) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28433888 | 0.94 | OPRM1 (0.90) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL28429546 | 0.93 | OPRM1 (0.88) | OPRM1SLC22A1ABCB1OPRD1OPRK1 | |
| Sufentanil SCHEMBL192322 | 0.92 | OPRM1 (0.85) | OPRM1SLC22A1ABCB1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616464-B1 | IMPROVED PROCESS FOR THE PREPARATION OF A PRECURSOR OF SUFENTANIL BASE | MALLINCKRODT LLC (US) | 2018-01-03 | — | — | EP | claimed |
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | MALLINCKRODT LLC (US) | 2012-03-22 | — | — | US | claimed |
| US-7302293-B2 | Device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION (US) | 2007-11-27 | — | — | US | claimed |
| US-20060275352-A1 | DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL | ALZA CORPORATION | 2006-12-07 | — | — | US | claimed |
| US-20050171464-A1 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2005-08-04 | — | — | US | claimed |
| US-20050131337-A1 | Method and device for transdermal delivery of fentanyl and sufentanil | ALZA CORPORATION | 2005-06-16 | — | — | US | claimed |
| US-6881208-B1 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2005-04-19 | — | — | US | claimed |
| EP-0836511-B1 | DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL | ALZA CORP (US) | 2004-04-07 | — | — | EP | claimed |
| CN-1118308-C | Device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORP (US) | 2003-08-20 | — | — | CN | claimed |
| US-20030083609-A1 | Device for transdermal electrotransport delivery of fentanyl and sufentanil | SOUTHAM MARY (US) | 2003-05-01 | — | — | US | claimed |
| US-6425892-B2 | ANALGESIC DRUG DELIVERY | ALZA CORPORATION | 2002-07-30 | — | — | US | claimed |
| US-20010018582-A1 | Device for transdermal electrotransport delivery of fentanyl and sufentanil | SOUTHAM MARY (US) | 2001-08-30 | — | — | US | claimed |
| US-6216033-B1 | Device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2001-04-10 | — | — | US | claimed |
| US-6171294-B1 | Method and device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORPORATION | 2001-01-09 | — | — | US | claimed |
| CN-1187142-A | Device for transdermal electrotransport delivery of fentanyl and sufentanil | ALZA CORP (US) | 1998-07-08 | — | — | CN | claimed |
| CN-1187140-A | Device for trandermal electrotransport delivery of fentanyl and sufentanil | ALZA CORP (US) | 1998-07-08 | — | — | CN | claimed |
| EP-0836511-A1 | DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL | ALZA CORPORATION (US) | 1998-04-22 | — | — | EP | claimed |
| WO-1996039222-A1 | DEVICE FOR TRANSDERMAL ELECTROTRANSPORT DELIVERY OF FENTANYL AND SUFENTANIL | ALZA CORPORATION (US) | 1996-12-12 | — | — | WO | claimed |
| CN-111419826-B | Sufentanil transdermal drug delivery pharmaceutical composition, preparation method and application thereof | 宜昌人福药业有限责任公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-1993001807-A1 | TRANSDERMAL DELIVERY DEVICE | ALZA CORPORATION (US) | 1993-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071659-A1 | Process for the Preparation of Sufentanil Base and Related Compounds | SNRPD1, SNRPD2, SNRPA1 | OPRM1 18/4885SLC22A1 2445/4885ABCB1 1242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.